BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $2.88.

BLRX has been the subject of several analyst reports. Zacks Investment Research upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. Roth Capital initiated coverage on BioLineRx in a report on Thursday, August 3rd. They issued a “buy” rating and a $3.00 price objective for the company. Oppenheimer Holdings, Inc. initiated coverage on BioLineRx in a report on Friday, August 4th. They issued an “outperform” rating and a $3.00 price objective for the company. Maxim Group set a $3.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, HC Wainwright set a $4.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th.

An institutional investor recently bought a new position in BioLineRx stock. Renaissance Technologies LLC acquired a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 131,480 shares of the biotechnology company’s stock, valued at approximately $126,000. Renaissance Technologies LLC owned about 0.21% of BioLineRx as of its most recent SEC filing. 32.59% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/19/biolinerx-ltd-blrx-receives-average-recommendation-of-buy-from-analysts.html.

Shares of BioLineRx (NASDAQ:BLRX) traded up $0.01 during midday trading on Friday, hitting $1.01. The stock had a trading volume of 255,589 shares, compared to its average volume of 282,078. BioLineRx has a 12 month low of $0.80 and a 12 month high of $1.38.

BioLineRx Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.